Brief: Rani Therapeutics Announces Repeat-Dose Topline Results From RT-102 Phase 1 Study

Rani Therapeutics Holdings

06/12/2022 21:14

Dec 6 (Reuters) - Rani Therapeutics Holdings Inc
 RANI.O :
    * RANI THERAPEUTICS ANNOUNCES REPEAT-DOSE TOPLINE RESULTS
FROM
RT-102 PHASE 1 STUDY
    * RANI THERAPEUTICS HOLDINGS INC - DATA FROM PART 1 AND PART
2 OF
PHASE 1 STUDY OF RT-102 SUPPORT ADVANCEMENT TO A PHASE 2 STUDY
    * RANI THERAPEUTICS HOLDINGS INC- RT-102 ACHIEVED ALL OF ITS
ENDPOINTS IN REPEAT-DOSE PART 2 OF PHASE 1 STUDY
    * RANI THERAPEUTICS HOLDINGS INC - REPEAT DOSES OF RT-102
WERE
GENERALLY WELL TOLERATED, WITH NO SERIOUS ADVERSE EVENTS
    * RANI THERAPEUTICS HOLDINGS INC- TWO SUBJECTS HAD
TRANSIENT,
MILD-TO-MODERATE ADVERSE EVENTS WHICH RESOLVED WITHOUT ANY
INTERVENTION

Source text for Eikon:  ID:nGNX671jWg 
Further company coverage:  RANI.O 
 ((Reuters.Briefs@thomsonreuters.com;;))